On February 29, 2019, the U.S. Food and Drug Administration (FDA) issued a safety communication warning the public about an increased risk of blood clots and death in patients with rheumatoid arthritis taking a high dose of Xeljanz (tofacitinib). The warning was prompted by a mandatory post-marketing safety trial of the drug. The trial is still … [Read more...]
Dangerous Drug Update: Uloric
The Food and Drug Administration (FDA) posted an urgent message on its website on February 21, 2019: “The FDA has concluded there is an increased risk of death with Uloric (febuxostat) compared to another gout medicine, allopurinol. This conclusion is based on our in-depth review of results from a safety clinical trial that found an increased risk … [Read more...]
Valsartan Lawsuits
Valsartan is the active pharmaceutical ingredient (API) in certain medications used to treat high blood pressure, congestive heart failure, and heart attack. It is sold in generic form and under the brand name Diovan. Valsartan is in a class of drugs called angiotensin II receptor blockers (ARBs). Valsartan produced by certain manufacturers, … [Read more...]
Drug Used to Treat Gout Is Dangerous, FDA Warns
On February 21, 2019, the Food and Drug Administration (FDA) posted the following urgent message on its website: “The FDA has concluded there is an increased risk of death with Uloric (febuxostat) compared to another gout medicine, allopurinol. This conclusion is based on our in-depth review of results from a safety clinical trial that found an … [Read more...]
Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets
Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg … [Read more...]
- 1
- 2
- 3
- …
- 40
- Next Page »
Recent Comments